The company manufactures and markets urine-based HIV-1 enzyme immunoassay screening test, which, when used with its Urine Western Blot supplemental test provides the urine-based HIV testing method.
Laboratories using this urine-based testing method can complete the testing profile for HIV-1 antibody using a single urine specimen.
The company also manufactures and markets the Cambridge Biotech serum-based western blot supplemental test for detecting HIV-1 antibodies in serum.
Calypte Biomedical is also developing new test products for the detection of HIV-1 and HIV Type 2, and other infectious diseases.
The company distributes its products in Brazil, Indonesia, South Africa, Uganda, Kenya, China, and Malaysia.
It has a 51% owned joint venture, Beijing Calypte Biomedical Technology, Ltd.
, in China with Marr Technologies Limited.
Calypte Biomedical was incorporated in 1989 and is headquartered in Alameda, California.
